Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

21.57 -0.02 (-0.09%)
Streaming Delayed Price Updated: 11:43 AM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Exelixis Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company... 
Via Benzinga
Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients
Exelixis Inc (NASDAQ: EXEL) has announced results from cohort 6 of the COSMIC-021 Phase 1b trial evaluating Cabometyx (cabozantinib) in combination... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers OptiNose (NASDAQ:OPTN) stock rose... 
Via Benzinga
Is Exelixis a Buy?
Revenue growth will probably accelerate soon, but it might not be enough. 
Via The Motley Fool
What Investors Should Look for With Exelixis, DermTech, and Teladoc Health
All three healthcare stocks could have solid growth prospects. 
Via The Motley Fool
Why Is GlaxoSmithKline Selling Its Income Stream to Royalty Pharma?
Apparently, up-front capital is better than royalties on drugs the pharma doesn't have control over. 
Via The Motley Fool
Exelixis Inc (EXEL) Q1 2021 Earnings Call Transcript
EXEL earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Exelixis: Q1 Earnings Insights
Shares of Exelixis (NASDAQ:EXEL) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 52.63% over the past year... 
Via Benzinga
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.